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Indoleamine 2, 3-dioxygenase (IDO1) is a cytosolic
enzyme catalyzing the oxidation of tryptophan to kynur-
enine. IDO1 plays an important role in modulating
immune responses in cancer, where increasing evidence
suggests that IDO1 expression by dendritic cells (DCs)
and other antigen-presenting cells (APCs) contributes to
tumor-mediated immune suppression. Programmed
death-ligand 1 (PD-L1) is a cell surface protein that is
broadly expressed by tumor cells and tumor-infiltrating
immune cells in many human cancers. Blockade of PD-
L1 or PD-1 with monoclonal antibodies results in strong
and often rapid anti-tumor effects in preclinical models
and in the clinic, where deep and durable objective
responses have been observed in a number of tumor
types including melanoma, NSCLC, renal and bladder
cancer. Accumulating preclinical and clinical data pro-
vide evidence that host immunosuppression by tumor
cells is mediated by multiple pathways, and therefore
combination therapy regimens employing one or more
targeted immunotherapy agents are necessary for more
complete and durable patient responses. The combina-
tion of IDO1 inhibition with PD-L1 blockade has strong
rationale since both checkpoints are co-expressed in
many cancers and inhibit immune responses via com-
plementary mechanisms. Using mouse syngeneic tumor
models we present further evidence of the therapeutic
potential of combining IDO1 inhibition with anti-PD-L1
blockade. We observe improved depth and duration of
responses in mice treated with the combination regimen
versus anti-PD-L1 blockade alone. These studies also reveal
potential immunomodulatory effects responsible for the
observed efficacy, namely an improved CD8:Treg ratio and
evidence of increased maturation and antigen presentation
capacity by DCs and APCs in the combination arm. Clini-
cal trials will further assess the potential of this promising
combination regimen in patients. A Phase Ib, open-label,
multicenter, global study is underway to evaluate the safety,
tolerability, and pharmacokinetics of the combination of
GDC-0919 and atezolizumab (MPDL3280A, anti-PD-L1)
in patients with locally advanced or metastatic incurable
solid tumors (NCT02471846).
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